First human test of new cancer drug combo for Tough-to-Treat lung tumors
Disease control
Ongoing
This early-stage study is testing a new combination of two immunotherapy drugs, obrixtamig and ezabenlimab, for adults with advanced small cell lung cancer or related neuroendocrine tumors that have stopped responding to standard treatments. The main goal is to find the highest d…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Apr 22, 2026 15:59 UTC